Mineralys Therapeutics, Inc. (MLYS)
MLYS price $21.10 -0.48 -2.22%
- Ticker
- MLYS
- Price
- $21.10
- Change
- -0.48 -2.22%
- Market cap
- $1.87B
- P/E
- -5.09
- Forward P/E
- 11.11
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 62
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally…